Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PRAVEEN KUMAR TUMULA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447402896
CMS profile
746364
Location
AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$340.16

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $179.92 3
Food and Beverage $160.24 3

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Epizyme, Inc., $125.00 1
Seagen Inc. $95.00 1
Incyte Corporation $60.99 1
Myovant Sciences Inc. $23.93 1
Amgen Inc. $21.12 1
JAZZ PHARMACEUTICALS INC. $14.12 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PRAVEEN KUMAR TUMULA

NPI 1447402896 · CMS profile ID 746364

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AMARILLO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PRAVEEN KUMAR TUMULA, NPI 1447402896, CMS profile ID 746364, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447402896?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $340.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Epizyme, Inc., $125.0011/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832343341 CMS
JAZZ PHARMACEUTICALS INC. $14.1211/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845605919 CMS
Seagen Inc. $95.0006/08/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832188317 CMS
Incyte Corporation $60.9905/03/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835550457 CMS
Myovant Sciences Inc. $23.9304/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834994241 CMS
Amgen Inc. $21.1201/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826537917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,168.66 28
PY2020 $4,815.65 8
PY2021 $340.16 6
PY2022 $1,916.32 26
PY2023 $4,540.57 16
PY2024 $2,679.61 6
PY2025 $6,258.84 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,557.82 36
PY2024 Principal investigator $1,085,444.24 161
PY2023 Principal investigator $684,815.25 77
PY2022 Principal investigator $638,195.90 127
PY2021 Principal investigator $416,830.90 164
PY2020 Principal investigator $201,522.62 122
PY2019 Recipient $1,287.72 1
PY2019 Principal investigator $54,363.67 98

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

122 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Celgene Corporation $3,000.00 12/16/2020 Non-covered Recipient Entity
Texas Oncology
Celgene - Connect MDS/AML No dispute reported 06/30/2026 736450669
Principal investigator 1 Incyte Corporation $105.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270345
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270347
Principal investigator 1 Incyte Corporation $105.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270349
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270351
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270353
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270355
Principal investigator 1 Incyte Corporation $105.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270357
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270359
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270361
Principal investigator 1 Incyte Corporation $105.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270363
Principal investigator 1 Incyte Corporation $489.00 12/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270365
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 12/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727739719
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 12/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727739723
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 12/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727740389
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,292.40 12/08/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737093907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $429.24 12/08/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737093913
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,716.96 12/08/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737093917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,863.16 12/08/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737093929
Principal investigator 1 Incyte Corporation $105.00 11/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270341
Principal investigator 1 Incyte Corporation $489.00 11/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270343
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 11/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727739697
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 11/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727740747
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 11/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727741027
Principal investigator 1 Incyte Corporation $4,017.23 11/05/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270333
Principal investigator 1 Incyte Corporation $850.00 10/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270335
Principal investigator 1 Incyte Corporation $105.00 10/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270337
Principal investigator 1 Incyte Corporation $489.00 10/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270339
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727739739
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 10/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727739823
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727740447
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727740499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,716.96 09/22/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737088935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,716.96 09/22/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737088955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,287.72 09/17/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737088483
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727732871
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733335
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733491
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733759
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733763
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734249
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734683
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734863
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734977
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734981
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735377
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735591
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735615
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735727
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735761
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727736421
Principal investigator 1 Incyte Corporation $489.00 08/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270321
Principal investigator 1 Incyte Corporation $105.00 08/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270323
Principal investigator 1 Incyte Corporation $489.00 08/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270325
Principal investigator 1 Incyte Corporation $105.00 08/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270327
Principal investigator 1 Incyte Corporation $105.00 08/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270329
Principal investigator 1 Incyte Corporation $489.00 08/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270331
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733325
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733713
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734649
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734783
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735151
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727735549
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727736225
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727736469
Principal investigator 1 Incyte Corporation $850.00 07/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270315
Principal investigator 1 Incyte Corporation $489.00 07/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270317
Principal investigator 1 Incyte Corporation $105.00 07/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,440.20 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084655
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,716.96 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,716.96 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084673
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.20 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084691
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.20 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,010.96 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084721
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,716.96 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084757
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,146.20 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $858.48 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS - THE INSIGHT - MM STUDY No dispute reported 06/30/2026 737084795
Principal investigator 1 Incyte Corporation $105.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270251
Principal investigator 1 Incyte Corporation $489.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270253
Principal investigator 1 Incyte Corporation $105.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270269
Principal investigator 1 Incyte Corporation $489.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270271
Principal investigator 1 Incyte Corporation $489.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270273
Principal investigator 1 Incyte Corporation $105.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270275
Principal investigator 1 Incyte Corporation $105.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270277
Principal investigator 1 Incyte Corporation $489.00 06/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270279
Principal investigator 1 Incyte Corporation $3,443.34 06/04/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270243
Principal investigator 1 BeiGene, Ltd. $56,376.00 06/01/2020 Non-covered Recipient Entity
Texas Oncology-Amarillo
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 753001159
Principal investigator 1 Incyte Corporation $489.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270247
Principal investigator 1 Incyte Corporation $105.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270249
Principal investigator 1 Incyte Corporation $489.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270259
Principal investigator 1 Incyte Corporation $489.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270261
Principal investigator 1 Incyte Corporation $489.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270263
Principal investigator 1 Incyte Corporation $105.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270265
Principal investigator 1 Incyte Corporation $489.00 05/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270267
Principal investigator 1 Incyte Corporation $105.00 04/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270229
Principal investigator 1 Incyte Corporation $850.00 04/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270231
Principal investigator 1 Incyte Corporation $489.00 04/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270245
Principal investigator 1 Incyte Corporation $105.00 04/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270255
Principal investigator 1 Incyte Corporation $489.00 04/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270257
Principal investigator 1 Celgene Corporation $6,405.00 02/17/2020 Non-covered Recipient Entity
Texas Oncology, Pa
Celgene - Connect MDS/AML No dispute reported 06/30/2026 736450563
Principal investigator 1 Incyte Corporation $489.00 02/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270187
Principal investigator 1 Incyte Corporation $105.00 02/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270189
Principal investigator 1 Incyte Corporation $489.00 02/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270191
Principal investigator 1 Incyte Corporation $105.00 02/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270193
Principal investigator 1 Incyte Corporation $4,591.12 02/13/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270179
Principal investigator 1 Incyte Corporation $38.32 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270211
Principal investigator 1 Incyte Corporation $76.64 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270213
Principal investigator 1 Incyte Corporation $57.00 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270215
Principal investigator 1 Incyte Corporation $54.90 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270217
Principal investigator 1 Incyte Corporation $0.40 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270219
Principal investigator 1 Incyte Corporation $1.50 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270221
Principal investigator 1 Incyte Corporation $57.00 02/10/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270227
Principal investigator 1 Incyte Corporation $850.00 01/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270181
Principal investigator 1 Incyte Corporation $489.00 01/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270183
Principal investigator 1 Incyte Corporation $105.00 01/15/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270185
Principal investigator 1 Incyte Corporation $76.64 01/09/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270201
Principal investigator 1 Incyte Corporation $0.40 01/09/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270203
Principal investigator 1 Incyte Corporation $54.90 01/09/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270205
Principal investigator 1 Incyte Corporation $57.00 01/09/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270207
Principal investigator 1 Incyte Corporation $1.50 01/09/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270209
Principal investigator 1 Incyte Corporation $57.00 01/09/2020 Non-covered Recipient Entity
TX ONC : AMARILLO
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744270225
Principal investigator 2 Celgene Corporation $65,518.21 01/02/2020 Non-covered Recipient Entity
Texas Oncology, Pa
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) No dispute reported 06/30/2026 736450539